Magenta Therapeutics

$10.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-0.87%) As of 4:40 PM UTC today

Why Robinhood?

You can buy or sell MGTA and other stocks, options, and ETFs commission-free!

About MGTA

Magenta Therapeutics, Inc. Common Stock, also called Magenta Therapeutics, is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA. The listed name for MGTA is Magenta Therapeutics, Inc. Common Stock.

CEO
Jason Gardner
Employees
72
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
452.30M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
517.68K
High Today
$10.32
Low Today
$9.51
Open Price
$9.90
Volume
258.74K
52 Week High
$12.63
52 Week Low
$5.76

MGTA Earnings

-$0.59
-$0.39
-$0.20
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market

You May Also Like

DAN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure